New York 2025 Session Status: Introduced

S9651 — Relates to utilization review program standards and pre-authorization for certain health care services

Last action — In Senate Committee

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed Assembly
  5. 5
    To Executive
  6. 6
    Enacted

This bill has been introduced in the Senate. Introduced March 31, 2026. It must pass committee before a floor vote.

Next likely step: a committee referral and hearing.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Not enough signal yet

Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

In plain language

Sets standards for healthcare utilization review programs and pre-authorization processes.

This bill establishes standards for utilization review programs in healthcare, focusing on evidence-based criteria. It also addresses changes to prescription drug formularies and the need for pre-authorization for specific health services.

What this means for you
  • Consumers: Patients may experience changes in how pre-authorization for treatments and medications is managed.
  • Healthcare: Healthcare providers will need to adhere to new standards for evaluating the necessity of services.

Summary

Relates to utilization review program standards; requires use of evidence-based and peer reviewed clinical review criteria; relates to prescription drug formulary changes and pre-authorization for certain health care services.

Bill Text

Action History

  1. COMMITTED TO RULES

  2. ADVANCED TO THIRD READING

  3. 2ND REPORT CAL.

  4. 1ST REPORT CAL.815

  5. REFERRED TO HEALTH

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 218 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (218)

218 members have not signed on to this bill.

Show all 218 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S9651 do?
Relates to utilization review program standards; requires use of evidence-based and peer reviewed clinical review criteria; relates to prescription drug formulary changes and pre-authorization for certain health care services.
Who sponsors S9651?
S9651 is sponsored by Gustavo Rivera.
What is the current status of S9651?
This bill has been introduced in the Senate. Introduced March 31, 2026. It must pass committee before a floor vote.
Where can I track S9651?
Track S9651 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S9651

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S9651

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →